Frequency of Hyperparathyroidism in Postmenopausal Osteoporosis and Its Treatment

• Status: Completed
• Trial end date: 2022-02-20
• Target enrollment: 0
• Participant gender: Female

Summary

Recently, an increase in the prevalence of hyperparathyroidism and hypovitaminosis D in postmenopause women has been occurring in Mexico and the world. Chronic exposure to the parathyroid hormone (PTH) is catabolic for the bone, worsening the state of osteoporosis. However, it is unclear whether these conditions could significantly improve bone mineral density (BMD). In the present work, it was shown that the resolution of hyperparathyroidism in postmenopausal women improves osteoporosis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Regional 1o de Octubre
• Collaborators: National Polytechnic Institute, Mexico; Universidad Nacional Autonoma de Mexico
• Treatments: Cholecalciferol

Criteria

Inclusion Criteria:

• Participants that accepted to participate in the study and provided informed consent.

• Participants that had the diagnosis of postmenopausal osteoporosis or osteopenia.

• Participants that had the diagnosis of hyperparathyroidism.

• Participants that had the diagnosis of vitamin D insufficiency or deficiency.

• Participants multi treated for postmenopausal osteoporosis.

• Participants without specific treatment for postmenopausal osteoporosis.

Exclusion Criteria:

• Participants with different osteoporosis aetiology not related to oestrogenic deficiency.

• Participants with thyroid pathology.

• Participants that had received previous treatment with vitamin D, thiazide diuretics, lithium, Teriparatide or glucocorticoids.

• Participants that had known allergies to vitamin D.

• Participants with Addison's disease, pheochromocytoma, and depressive disorders.